Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering Journal Article


Authors: Odak, A.; Yuan, H.; Feucht, J.; Cantu, V. A.; Mansilla-Soto, J.; Kogel, F.; Eyquem, J.; Everett, J.; Bushman, F. D.; Leslie, C. S.; Sadelain, M.
Article Title: Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering
Abstract: Cell therapies that rely on engineered immune cells can be enhanced by achieving uniform and controlled transgene expression in order to maximize T-cell function and achieve predictable patient responses. Although they are effective, current genetic engineering strategies that use γ-retroviral, lentiviral, and transposon-based vectors to integrate transgenes, unavoidably produce variegated transgene expression in addition to posing a risk of insertional mutagenesis. In the setting of chimeric antigen receptor (CAR) therapy, inconsistent and random CAR expression may result in tonic signaling, T-cell exhaustion, and variable T-cell persistence. Here, we report and validate an algorithm for the identification of extragenic genomic safe harbors (GSH) that can be efficiently targeted for DNA integration and can support sustained and predictable CAR expression in human peripheral blood T cells. The algorithm is based on 7 criteria established to minimize genotoxicity by directing transgene integration away from functionally important genomic elements, maximize efficient CRISPR/Cas9–mediated targeting, and avert transgene silencing over time. T cells engineered to express a CD19 CAR at GSH6, which meets all 7 criteria, are curative at low cell dose in a mouse model of acute lymphoblastic leukemia, matching the potency of CAR T cells engineered at the TRAC locus and effectively resisting tumor rechallenge 100 days after their infusion. The identification of functional extragenic GSHs thus expands the human genome available for therapeutic precision engineering. © 2023 The American Society of Hematology
Keywords: controlled study; human cell; nonhuman; antigen expression; animal cell; mouse; cancer immunotherapy; animal experiment; animal model; in vivo study; antineoplastic activity; in vitro study; acute lymphoblastic leukemia; algorithm; transgene; genomics; chimeric antigen receptor; gene silencing; genotoxicity; dna integration; cell engineering; human; male; article; crispr-cas9 system; adeno associated virus 6; genomic safe harbor
Journal Title: Blood
Volume: 141
Issue: 22
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2023-06-01
Start Page: 2698
End Page: 2712
Language: English
DOI: 10.1182/blood.2022018924
PUBMED: 36745870
PROVIDER: scopus
PMCID: PMC10273162
DOI/URL:
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Michel Sadelain -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michel W J Sadelain
    583 Sadelain
  2. Christina Leslie
    188 Leslie
  3. Justin Gabriel Andre Francois Eyquem
    25 Eyquem
  4. Han   Yuan
    8 Yuan
  5. Judith Carolin Feucht
    23 Feucht
  6. Ashlesha Odak
    9 Odak
  7. Friederike Kogel
    5 Kogel